Dermatomyositis and Polymyositis

There is a great unmet need for new treatments in the inflammatory myopathies.  We have participated in a phase 1b study of the anti-CD20 small modular immunopharmaceutical TRU-15 for polymyositis and dermatomyositis.   In addition, Dr. Eggebeen, who has advanced training in myositis care at the University of Pittsburg, had done translational research linking myositis associated antibodies to the development of intersitial lung disease.  Subsequently Dr. Eggebeen was a principle investigator in the National Institute of Health funded, first of it kind trial the "Rituximab in Myositis Study".  

Enrollment is now closed for this study, but if you are interested you can learn more at ClinicalTrials.gov 

©2015 West Michigan Rheumatology, PLLC                1155 East Paris SE, Suite 100                              Grand Rapids, MI 49546                                               Voice 616.459.8088                                                       FAX 616.459.8312                                                www.mi-arthritis.com